Standl T, Burmeister M A, Horn E P, Wilhelm S, Knoefel W T, Schulte am Esch J
Department of Anaesthesiology, University Hospital Eppendorf, Hamburg, Germany.
Br J Anaesth. 1998 Feb;80(2):189-94. doi: 10.1093/bja/80.2.189.
We have studied the use of ultrapurified polymerized bovine haemoglobin (HBOC-201) in patients undergoing preoperative haemodilution before liver resection. After autologous blood donation of 1 litre, 12 patients (six males, six females, mean age 59 (35-69) yr) received Ringer's lactate solution 2 litre and, in a random design, 6% hydroxyethyl starch 70,000/0.5 (HES) 3 ml kg-1 or HBOC-201 0.4 g kg-1 within 30 min. Blood samples were obtained for blood chemistry, co-oximetry, haematology, coagulation profiles and immunology examinations before operation, on the day of surgery, on days 2-4 and 7 after operation, on the discharge day and 3 months after operation. There were no differences in patient characteristics, blood loss, amount of solutions infused, transfused allogeneic blood or duration of hospital stay. There were no local or systemic allergic reactions with infusion of HES or HBOC-201. Patients receiving HBOC-201 developed more pronounced leucocytosis and reticulocytosis during the early postoperative days compared with HES-treated patients. The mean maximum plasma haemoglobin concentration was 1.0 (SD 0.2) g dl-1 at the end of infusion of HBOC-201 was 8.5 h. Patients in both groups experienced temporary changes in liver enzymes and coagulation variables which returned to normal before discharge. Urinalysis revealed no difference between groups and no free haemoglobin was detected in urine. Patients receiving HBOC-201 showed no IgE and only a slight increase in IgG titres to HBOC-201 on the day of discharge; these were not detectable at 3 months. Single-dose administration of HBOC-201 was well tolerated by patients undergoing elective liver resection surgery and appears to be safe as a substitute during preoperative haemodilution.
我们研究了超纯聚合牛血红蛋白(HBOC-201)在肝切除术前进行血液稀释的患者中的应用。在自体献血1升后,12例患者(6例男性,6例女性,平均年龄59(35 - 69)岁)接受2升乳酸林格氏液,并采用随机设计,在30分钟内给予6%羟乙基淀粉70,000/0.5(HES)3 ml/kg或HBOC-201 0.4 g/kg。在手术前、手术当天、术后第2 - 4天和第7天、出院当天以及术后3个月采集血样进行血液化学、共血氧测定、血液学、凝血指标和免疫学检查。患者的特征、失血量、输注溶液量、输注异体血或住院时间均无差异。输注HES或HBOC-201均未出现局部或全身过敏反应。与接受HES治疗的患者相比,接受HBOC-201的患者在术后早期出现更明显的白细胞增多和网织红细胞增多。在输注HBOC-201结束时8.5小时,平均最大血浆血红蛋白浓度为1.0(标准差0.2)g/dl。两组患者的肝酶和凝血变量均出现暂时变化,出院前恢复正常。尿液分析显示两组之间无差异,尿液中未检测到游离血红蛋白。接受HBOC-201的患者在出院当天未显示IgE,对HBOC-201的IgG滴度仅略有增加;在3个月时未检测到这些变化。接受择期肝切除手术的患者对单剂量HBOC-201耐受性良好,并且在术前血液稀释期间作为替代品似乎是安全的。